▲ Peaking
Business
Kyverna ‘resetting conversation’ with 1-year miv-cel data as autoimmune CAR-T peers hit safety snags
Kyverna is leveraging one-year miv-cel durability data to position its CAR T-cell therapy as a leading autoimmune treatment amid peer safety concerns.